Loading...

Home
ETF
MDCX

MDCX

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

MDCX News

Medicus Pharma Submits Rare Pediatric Disease Designation for SkinJect

4d agoNASDAQ.COM

Medicus Pharma Submits Rare Pediatric Disease Application

5d agoNewsfilter

Medicus Pharma Submits IND Application for Teverelix Trial in UAE

Jun 12 2026NASDAQ.COM

Medicus Pharma Submits IND Application for Teverelix®

Jun 11 2026Newsfilter

Medicus Pharma Submits Clinical Trial Application for Teverelix®

Jun 08 2026Newsfilter

Medicus Pharma Secures $22 Million Financing Agreement

May 29 2026NASDAQ.COM

Medicus Pharma Reports Q1 Financial Results

May 14 2026seekingalpha

Medicus Pharma Reports Q1 2026 Financial Results and Corporate Update

May 14 2026Newsfilter

Medicus Pharma Reports Positive Clinical Results for D-MNA

May 06 2026Newsfilter

Medicus Pharma Advances SkinJect Development for Gorlin Syndrome

Apr 27 2026Newsfilter

Highlights from New to The Street Broadcast

Apr 25 2026Yahoo Finance

Medicus Pharma Submits Orphan Drug Designation for SkinJect®

Apr 17 2026Newsfilter

Medicus Pharma Files Application for Orphan Drug Designation with U.S. FDA for Skinject® in Gorlin Syndrome

Apr 17 2026moomoo

Medicus Pharma Presents Phase 1 Data on Teverelix at AACE 2026

Apr 15 2026Newsfilter

Medicus Pharma Submits New Drug Study Protocol to FDA

Apr 06 2026NASDAQ.COM

Medicus Pharma Submits Optimized Phase 2 Study Design for Teverelix

Apr 06 2026Newsfilter